Maridebart Cafraglutide (10mg)
Monthly-Dosed GIP-Antagonist / GLP-1-Agonist Conjugate
Maridebart Cafraglutide (MariTide) is listed for glp-1 & metabolic laboratory research. Catalog vial contents are 10mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
Research Applications & Benefits
- First-in-class peptide-antibody conjugate
- Monthly-dose pharmacokinetics in research models
- GLP-1 agonism + GIP antagonism mechanism
- Investigational obesity & T2D research tool
What is Maridebart Cafraglutide (MariTide)?
Maridebart cafraglutide, also called AMG 133 or MariTide, is studied as a peptide-antibody conjugate. Its clinical construct combines GLP-1 activity with an antibody that blocks GIP receptors. The catalog lists a 10mg material whose exact construct needs confirmation.
Listed vial contents: 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.
Which identity should I verify?
The published molecule includes an antibody domain and attached GLP-1 analogues. The catalog's approximate molecular weight does not establish equivalence to that complete conjugate. A peptide fragment cannot be assumed to reproduce the antibody's GIP-receptor activity; obtain matching construct and identity documentation.
What mechanisms are being studied?
GLP-1 agonism activates a receptor, while GIP antagonism blocks another receptor's signaling. This differs from tirzepatide, which activates both receptors. The antibody scaffold is central to interpreting the published conjugate's pharmacology.
What are the research questions?
- GLP-1 activation combined with GIP receptor blockade
- Antibody-conjugate versus peptide-fragment identity
- Construct-dependent receptor binding and pharmacology
What does the published work describe?
Véniant and colleagues' 2024 paper describes preclinical and phase 1 work on the antibody-peptide conjugate. It is evidence about that defined construct, not about an unspecified peptide sold under the same name. The page does not infer matching activity from the catalog label.
Experimental models in the cited papers
- Preclinical studies and phase 1 human research; defined AMG 133 antibody-peptide conjugate
What could future research explore?
Future research can distinguish the roles of the peptide and antibody domains. Meaningful comparisons require complete construct characterization before extrapolating conjugate findings to another research material.
These are research directions, not established applications of the product sold here.
What are the limits of this evidence?
An unresolved construct prevents direct attribution of the published conjugate's properties to this supplied material. Clinical findings apply to the tested formulation, trial population and study conditions. They do not establish the identity, safety or effectiveness of this laboratory vial. Research Use Only: this material is not a finished medicine.
Study references
- Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024. PMID 38316982
How should I check lot documentation?
Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.
How is Maridebart Cafraglutide (MariTide) handled in the lab?
For Maridebart Cafraglutide (MariTide), record the product code MARI-10, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
For Maridebart Cafraglutide (MariTide), establish the supplied preparation or construct, formulation and activity documentation before dilution. Protein folding, aggregation, adsorption and excipient compatibility can affect assays. Evaluate compatible vessels and buffer conditions in a small study; do not add a carrier protein unless it is appropriate for the assay and documented in the SOP.
For Maridebart Cafraglutide (MariTide), calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~6800 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
Use the documented storage conditions for the supplied Maridebart Cafraglutide (MariTide) form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
A Maridebart Cafraglutide (MariTide) laboratory protocol should record identity, product code MARI-10, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Research Use Only. Not for human consumption, therapeutic, veterinary or any in-vivo use.
Product Specifications
- Compound
- Maridebart Cafraglutide (MariTide)
- CAS Number
- 2762747-50-2
- Molecular Weight
- ~6800 g/mol
- HPLC Purity Specification
- ≥99%
- Category
- GLP-1 & Metabolic
- Starting Price
- $329.00 USD
- Country of Origin
- United States
- Shipping
- Cold-chain insulated packaging, fast domestic delivery
- Payment
- Card, ACH, and cryptocurrency (10% discount)
Quality & Verification
Maridebart Cafraglutide (MariTide) has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
Frequently Asked Questions
What is Maridebart Cafraglutide (MariTide)?
Maridebart Cafraglutide (MariTide) is listed for glp-1 & metabolic laboratory research. Catalog vial contents are 10mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
What strengths of Maridebart Cafraglutide (MariTide) are available?
The catalog lists 10mg. These labels describe vial contents, not administration doses. Select the required strength for current pricing and availability; match analysis records to that exact strength and lot.
How should I interpret Maridebart Cafraglutide (MariTide) purity results?
Maridebart Cafraglutide (MariTide) has a catalog purity specification of ≥99%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
How should Maridebart Cafraglutide (MariTide) be handled in the laboratory?
For Maridebart Cafraglutide (MariTide), record the product code MARI-10, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
How do I choose a laboratory solvent for Maridebart Cafraglutide (MariTide)?
For Maridebart Cafraglutide (MariTide), establish the supplied preparation or construct, formulation and activity documentation before dilution. Protein folding, aggregation, adsorption and excipient compatibility can affect assays. Evaluate compatible vessels and buffer conditions in a small study; do not add a carrier protein unless it is appropriate for the assay and documented in the SOP.
How do I calculate a Maridebart Cafraglutide (MariTide) stock concentration?
For Maridebart Cafraglutide (MariTide), calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~6800 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
How should Maridebart Cafraglutide (MariTide) be stored after preparation?
Use the documented storage conditions for the supplied Maridebart Cafraglutide (MariTide) form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
What should a Maridebart Cafraglutide (MariTide) lab protocol document?
A Maridebart Cafraglutide (MariTide) laboratory protocol should record identity, product code MARI-10, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Does Fmoc or Boc synthesis explain this Maridebart Cafraglutide (MariTide) product?
The catalog name Maridebart Cafraglutide (MariTide) alone does not establish a synthetic, recombinant or preparation-specific production route. Confirm construct or preparation documentation and relevant analytical or activity methods before drawing conclusions from a peptide synthesis guide.
Is Maridebart Cafraglutide (MariTide) for human use?
No. Maridebart Cafraglutide (MariTide) is strictly Research Use Only. It is not intended for human or veterinary use, diagnosis or treatment. Laboratory handling guidance is not an administration protocol.
Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.
